Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation . Its primary technology platforms are Therapeutic DNA vaccine and hyFc® long-acting technology and bioPROTAC. The company has multiple products in clinical development including several undergoing Phase 3 registrational trials. The company's proprietary pipeline includes GX-188E (tirvalimogene teraplasmid) for head and neck cancer and cervical cancer, GX-I7 (efineptakin alfa) for multiple solid cancers and ARS, GX-H9 (eftansomatropin alfa) for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. in 2024, Genexine has completed a merger with 'EPD biotherapeutics' and acquired future focusing new modality 'bioPROTAC' platform technology which now in pre-clinical development focusing on oncology. The company has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide. For more information about Genexine, please visit at www.genexine.com.
我們正在追蹤 Genexine, Inc. 的市場擴張
Genexine, Inc. 的國際擴張與競爭對手的比較
Genexine, Inc.你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Genexine, Inc.你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
韓國政府增加生物技術研發預算，專注於人工智能驅動的抗體開發和生物仿製藥項目。預計普羅蒂納和基因信等公司將受益。
Oscotech舉行在線簡報會，解釋子公司Genexine上市的必要性和未來股東回報計劃，強調這不是分拆上市，而是研發資金的必要策略。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Genexine, Inc. 業務、市場及增長訊號的快速解答。
